Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
Carlos Garberoglio, MD
Chair, Surgery
School of Medicine
Head, Surgery, Surgical Oncology Division
School of Medicine
Professor, Surgery
School of Medicine
Professor, Basic Sciences
School of Medicine
Research & Grantsmanship    Funded Research Project (PI)
  • A randomized trial of axillary node dissection in women with clinical T1 or T2 NO M0 breast cancer who have a positive sentinel node. ( 4/2004 - 12/2004 )
  • Study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer. ( 4/1999 - 8/2004 )
  • A randomized, phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. ( 9/2000 - 2/2004 )
  • A clinical trial to evaluate the benefit of adding octreotide (SMS 201-995 pa LAR) to tamoxifen alone or to tamoxifen and chemo in patients with axillary node-negative, estrogen-receptor-positive, primary invasive breast cancer. ( 8/1997 - 12/1999 )
  • A clinical trial to evaluate the worth of preoperative multimodality therapy (dFU-LV and RTX) in patients with operable carcinoma of the rectum. ( 12/1993 - 6/1999 )
  • A clinical trial comparing short, intensive AC with or without tamoxifen with conventional CMF with or without tamoxifen in node-negative breast cancer patients with ER-negative tumors. ( 9/1991 - 12/1998 )
  • A clinical trial to determine the worth of tamoxifen and the worth of breast radiation in the management of patients with node-negative, occult, invasive breast cancer treated by lumpectomy. ( 4/1987 - 12/1998 )
  • A randomized trial evaluating the worth of paclitaxel (taxol) following doxorubicin (adriamycin)/cyclophosphamide in breast cancer patients with positive axillary nodes. ( 11/1995 - 5/1998 )
  • A clinical trial to determine the worth of tamoxifen for preventing breast cancer. ( 11/1996 - 12/1997 )
  • A clinical trial to evaluate the worth of tamoxifen in conjunction with lumpectomy and breast irradiation for the treatment of noninvasive intraductal carcinoma (DCIS) of the breast. ( 9/1992 - 4/1994 )
  • A clinical trial to assess the relative efficacy of 5-FU + leuvorin with or without interferon alfa-2a in patients with dukes'' B and C carcinoma of the colon. ( 3/1992 - 2/1994 )
  • A "unified" trial to compare short, intensive preoperative systemic adriamycin cyclophosphamide threapy with similary therapy administered in conventional postoperative fashion ( 9/1991 - 4/1993 )
  • A clinical trial to determine the worth of chemotherapy and tamoxifen or tamoxifen alone in the management of patients with primary invasive breast cancer, negative, axillary nodes and estrogen-receptor-positive tumors. ( 9/1991 - 3/1993 )
  • A phase III, adjuvant trial comparing three chemotherpay regiments in women with node-positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD. Paclitaxel; (DD AC followed by DD P) ( 10/2004 - Present )
  • A phase III clinical trial comparing infusional 5-fluorouracil(5-FU), leucovorin, and oxaliplatin (mFOLFOX6). Every two weeks with bevacizumab to the same regimen without bevacizumab for the treatment of patients with resected stages II and III carcinoma. ( 9/2004 - Present )
  • A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC), with or without celecoxib, in patients with node-negative breast cancer. ( 6/2004 - Present )
  • Sentinel Lymph Node Working Group Data Acquisition Project ( 2/2004 - Present )
  Funded Research Project (CI)
  • A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that of adriamycin and cyclophosphamide  followed by taxol plus herceptin (AC-T+HC) in node-positive breast cancer patients who have tumors. PI: Howard ( 4/2000 - 4/2005 )
  • A study comparing adjuvant clodronate therapy with placebo in patients with early-stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy. PI: Howard ( 12/2002 - 3/2004 )
  • A three-arm randomized trial to compare adjuvant adraimycin and cyclophosphamide followed by taxotere (AC-T); adriamycin and taxotere (AT); and adriamycin, taxotere, and cyclophosphamide (ATC) in breast cancer patients with positive axillary lymph nodes. PI: Howard ( 3/1999 - 3/2004 )
  • A clinical trial comparing 5-fluorouracil (5-FU) plus leucovorin (LV) and oxaliplatin with 5-FU plus LV for the treatment of patients with stages II and III carcinoma of the colon. PI: Godfrey ( 5/2000 - 11/2002 )
  • A trial evaluate the worth of serum ErbB-2 extracellular domain and serum ErbB-2 antibodies in predicting response to preoperative chemo and long term - term outcome in patients with operable breast cancer who are participating in NSABP protocol B-27. PI: Howard. ( 4/1997 - 12/2000 )
  • A randomized trial comparing preoperative doxorubicin (adriamycin) cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel in patients with operable carcinoma of the breast. PI: Howard ( 3/1996 - 12/2000 )
  • A clinical trial comparing oral uracil/ftorafur (UFT) plus lecovorin (LV) with 5 fluorouracil (5-FU) plus LV in the treatment of patients stages II and III carcinoma of the colon. PI: Wilbur ( 7/1997 - 3/1999 )
  • A clinical trial comparing oral uracil/ftorafur(UFT) plus leucovorin (LV) with 5 fluorouracil(5-FU) plus LV in the treatment of patients stages II and III carcinoma of the colon. PI: Howard ( 4/1997 - 3/1999 )
  • A phase I/II neoadjuvant study of capecitabine, irinotecan, celecoxib and radiation therapy in patients with locally advanced rectal cancer. PI: Malik ( 1/2003 - 7/0000 )
  • A multicenter, prospective, blinded-reader study to determine the sensitivity and specificity of the comfort scan system to detect malignancy as an adjunct to mammography in patients 50 years of age. PI: Bae ( 5/2005 - Present )
  • A clinical trial comparing anastrozole with tamoxifen  in postmenopausal patients with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy. PI: Howard ( 10/2003 - Present )